MedicinesHost Response with Novel Nanoproresolving Inflammation in Mice: Reprogramming the Aging Delays Resolution of Acute
暂无分享,去创建一个
[1] T. Harrer,et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines , 2014, Nature Medicine.
[2] Ruth R. Montgomery,et al. Age-dependent dysregulation of innate immunity , 2013, Nature Reviews Immunology.
[3] D. Gilroy,et al. Pathways mediating resolution of inflammation: when enough is too much , 2013, The Journal of pathology.
[4] C. Serhan,et al. Resolution phase lipid mediators of inflammation: agonists of resolution. , 2013, Current opinion in pharmacology.
[5] J. Haeggström,et al. The novel 13S,14S ‐epoxy‐maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] Tissue macrophage heterogeneity: issues and prospects , 2013, Seminars in Immunopathology.
[7] D. Cai,et al. Hypothalamic Programming of Systemic Aging Involving IKKβ/NF-κB and GnRH , 2013, Nature.
[8] W. Zhou,et al. Resolvin D1, an Endogenous Lipid Mediator for Inactivation of Inflammation‐Related Signaling Pathways in Microglial Cells, Prevents Lipopolysaccharide‐Induced Inflammatory Responses , 2013, CNS neuroscience & therapeutics.
[9] Y. Kawaoka,et al. The Lipid Mediator Protectin D1 Inhibits Influenza Virus Replication and Improves Severe Influenza , 2013, Cell.
[10] P. Calder. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? , 2013, British journal of clinical pharmacology.
[11] Ira Tabas,et al. Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013, Science.
[12] Elisabeth Wong,et al. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions , 2012, Proceedings of the National Academy of Sciences.
[13] S. Dakin,et al. Inflamm-Aging and Arachadonic Acid Metabolite Differences with Stage of Tendon Disease , 2012, PloS one.
[14] M. Giera,et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. , 2012, Biochimica et biophysica acta.
[15] C. Serhan,et al. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. , 2012, Blood.
[16] Trevor A. Mori,et al. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. , 2012, Clinical chemistry.
[17] Charles N. Serhan,et al. Infection Regulates Pro-Resolving Mediators that Lower Antibiotic Requirements , 2012, Nature.
[18] Alberto Mantovani,et al. Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.
[19] Ruth C Lovering,et al. Transcriptomic analyses of murine resolution-phase macrophages. , 2011, Blood.
[20] V. Arroyo,et al. Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype , 2011, The Journal of Immunology.
[21] E. Motta,et al. The precursor of resolvin D series and aspirin‐triggered resolvin D1 display anti‐hyperalgesic properties in adjuvant‐induced arthritis in rats , 2011, British journal of pharmacology.
[22] Yunan Tang,et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese‐diabetic mice , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[23] K. Swedberg. n-3 Fatty acids in cardiovascular disease. , 2011, The New England journal of medicine.
[24] M. Perretti,et al. Cutting Edge: Humanized Nano-Proresolving Medicines Mimic Inflammation-Resolution and Enhance Wound Healing , 2011, The Journal of Immunology.
[25] C. Serhan,et al. Saturated‐efferocytosis generates pro‐resolving CD11blow macrophages: Modulation by resolvins and glucocorticoids , 2011, European journal of immunology.
[26] M. Perretti,et al. Fundamentals of Inflammation: Models of Acute Inflammation – Air-Pouch, Peritonitis, and Ischemia-Reperfusion , 2010 .
[27] M. Pomponi,et al. Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. , 2010, Aging and disease.
[28] Charles N. Serhan,et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.
[29] C. Serhan,et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression , 2006, Nature Immunology.
[30] G. Davı̀,et al. Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels , 2005, Experimental Gerontology.
[31] Shubhada Sankararaman,et al. Cells, tissues and disease: Principles of general pathology , 1997 .
[32] C. Serhan,et al. Resolvins , 2002, The Journal of experimental medicine.
[33] J. Morrow,et al. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. , 1994, The Journal of biological chemistry.
[34] P. Poubelle,et al. Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E2. , 1985, Prostaglandins.